中文

濮阳惠成 Revenue Breakdown

Period 2026-03-31 ・ Reported 2026-04-24
ItemAmountY/Y
Revenue¥0.35B-0.9%
Gross profit¥0.07B
Operating income¥0.02B
Net income¥0.02B-49.2%
Gross margin19.2%Net margin 5.2%
Revenue Q/Q+3.4%

Revenue Segments

The filing did not disclose a revenue breakdown for this period.

Costs & Expenses

ItemAmount% of revenue
Cost of revenue¥0.29B80.8%
R&D¥0.02B6.2%
SG&A¥0.01B3.8%
Tax & other¥0.00B0.7%
Generate the full Sankey chart →

The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.

Other companies

万孚生物首华燃气蓝海华腾赛升药业东杰智能蓝晓科技恒锋工具光智科技华自科技通合科技华图山鼎润欣科技

Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies